Key Highlights:
Organon & Co. (NYSE: OGN) is a global healthcare company focused on women's health. The company, spun off from Merck, develops and commercializes medicines and products in areas such as reproductive health, contraception, and biosimilars. It is listed on the New York Stock Exchange.
Prior to the recent takeover reports, Organon shares had declined roughly 40% over the past year amid operational pressures and broader sector challenges. This decline appears to have drawn the attention of potential acquirers.
On April 10, 2026, reports emerged that Mumbai-based Sun Pharmaceutical Industries is advancing toward a $12 billion binding all-cash offer for Organon. According to sources cited by The Economic Times, Sun Pharma has completed more than three months of extensive due diligence and is finalizing financing arrangements before submitting the formal bid in the coming weeks. If completed, this would represent the largest overseas acquisition by an Indian pharmaceutical company.
The potential deal values Organon at a significant premium to its recent market capitalization of approximately $1.8–2 billion and its enterprise value of roughly $9.8–10 billion (which includes net debt).
Analyst support for a higher valuation was reinforced on the same day when BNP Paribas reiterated an Outperform rating with a $12.00 price target. At pre-news trading levels around $6.91–$8.68, this implied meaningful upside. Some commentary suggests that a $12 billion enterprise value transaction could translate to approximately $15 per share, offering even greater potential returns.
The market reacted strongly to the news, with Organon shares rising sharply — up as much as 20–26% — as investors priced in the takeover premium. This positive reaction underscores confidence that the offer reflects strategic value in Organon’s women’s health portfolio, including key products like Nexplanon.
